Navigation Links
Imagenetix Enters into Business Relationship with MonaVie

SAN DIEGO, June 2 /PRNewswire-FirstCall/ -- Imagenetix, Inc. (OTC Bulletin Board: IAGX) announced today that it has entered into a business relationship with MonaVie LLC ( that provides for Celadrin(R) to be utilized in MonaVie Active.

Celadrin, a cellular lubricant, is a joint health breakthrough that provides fast, long lasting joint comfort. Providing continuous lubrication, Celadrin improves cell membrane fluidity and elasticity. Celadrin is a unique, scientifically arranged matrix of all natural, esterified oil. Further, Celadrin has been subjected to over 17 scientific studies at leading universities and pharmaceutical laboratories throughout the world, with the results published in medical journals.

"We are extremely excited about the future of MonaVie as it relates to our relationship with Imagenetix," said Dallin Larsen, of MonaVie. "Celadrin is a reputable and proven product that fits well with MonaVie's mission to provide our consumers with products that promote healthy, active lifestyles."

"Imagenetix has the utmost confidence in MonaVie and its executive team, and are proud to be their associates," said Bill Spencer, of Imagenetix. "Considering what both companies bring to the table in terms of product quality and industry experience, this business partnership just makes sense. Based on this relationship we expect MonaVie to become one of our largest customers."

About MonaVie

MonaVie LLC is a rapidly growing company that distributes products to markets around the world. Introduced in January 2005, MonaVie develops and markets scientifically formulated, premium quality products, specifically for person-to-person distribution. Developed with a philosophy of Balance-Variety-Moderation, MonaVie brand products deliver phytonutrients and antioxidants to promote and maintain a healthy and active lifestyle. For more information about MonaVie brand products or how to join the MonaVie family, call 1-866-217-8455, or visit

About Imagenetix

Based in San Diego, California, Imagenetix, (OTCBB: IAGX) is an innovator of scientifically tested, natural-based, proprietary, bioceutical products developed to enhance human health on a global basis. Imagenetix develops and formulates private-labels, propriety over-the-counter topical creams, skincare products and nutritional supplements to be marketed globally through multiple channels of distribution. In addition, the company develops patentable compounds for entering into licensing agreements with pharmaceutical partners. Imagenetix is the creator of Inflame Away(R)-Celadrin(R), which has been clinically tested to relieve osteoarthritis pain and significantly improve joint health. For more information on Celadrin(R), please visit, or

SOURCE Imagenetix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Kroger and The Little Clinic Establish Partnership to Offer Customers Convenient Healthcare Centers Inside Their Neighborhood Store
2. Fitworks Fitness Centers Responds to the Growing Adolescent Obesity Rate by Offering Free Summer Memberships to Teens 13-15 Years of Age
3. China Pharma Holdings, Inc. Enters Into Private Placement Agreements to Raise $10 Million
4. Seahorse Bioscience Enters into Agreement with Primetech Corporation to Bring XF Technology to Japanese Market
5. Phyhealth Enters Agreement with Merrill Lynch to Manage Capital Surplus Funds for Phyhealth Pilot HMO
6. Widespread airbag use could result in dramatic cost savings for US trauma centers
7. Partnership of academic centers and community hospitals effective model for disseminating advances
8. Cancer Centers of North Carolina Receives Prestigious Accreditation
9. General Nutrition Centers, Inc. Reports First Quarter 2008 Financial Results
10. Centers for Medicare & Medicaid Services Awards Ogilvy Public Relations Worldwide $1.4 Million Dollar Contract
11. Flip Flops, Mulch and No Coat: Study Identifies Surprising Barriers to Outdoor Activity for Kids in Child-Care Centers
Post Your Comments:
(Date:11/26/2015)... ... November 26, 2015 , ... Patients at Serenity ... have come together on Thanksgiving Day to share the things that they are ... the Serenity Point YouTube channel, patients displayed what they wrote on index cards, ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... ... a real-time eReferral system for diagnostic imaging in the Waterloo region. Using the ... and Nuclear Medicine tests directly from their electronic medical record (EMR) without the ...
(Date:11/26/2015)... ... , ... The Catalent Applied Drug Delivery Institute today announced ... form selection in early phase drug development. The first of these is to ... the UK’s emerging life sciences companies, corporate partners, and investors, at Milton Park, ...
(Date:11/26/2015)... ... November 26, 2015 , ... PRMA Plastic Surgery is updating their record books ... their 6,000th free flap breast reconstruction surgery! , “What an accomplishment for the PRMA ... rebuild lives and it’s an honor to have served all of these women.” , ...
(Date:11/26/2015)... ... 26, 2015 , ... Pixel Film Studios brings Final Cut ... Vintage. This newly styled ProTrailer pack comes with 30 all-new vintage-inspired designs, with ... users limitless opportunities to stylize and create designs quickly and easily, all within ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 ... the "Self Administration of High Viscosity Drugs" ... ) has announced the addition of the ... report to their offering. --> Research ... addition of the "Self Administration of High ...
(Date:11/25/2015)... , Nov. 26, 2015  The total global healthcare industry ... over 2015-2016. Latin America has the ... , (excluding Japan ), is second with ... continues to face increased healthcare expenditure. In 2013-2014, total government ... from 43.5% in 2008-2009 to 41.2% in 2013-2014. In real ...
(Date:11/25/2015)... , Nov. 25, 2015 On Tuesday, ... federal bellwether trial against Wright Medical Technology, Inc. ... their Conserve metal-on-metal hip implant device, awarded $11 ... a two week trial and three days of ... hip device was defectively designed and unreasonably dangerous, ...
Breaking Medicine Technology: